New
SLU-PP-332
59,95 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Exercise mimicry: metabolic adaptations without physical exertion.
- Improved mitochondrial density and respiratory capacity.
- Increased endurance and fat oxidation.
- Potential effects on muscle aging and atrophy.
- Prevention of metabolic disease without the need for exercise.
- Synergy with AICAR for a comprehensive simulation of exercise.
Description
SLU-PP-332
Exercise Mimic / Metabolism
MECHANISM OF ACTION
A potent, non-selective agonist of ERR, an estrogen-related receptor, with primary activity on ERRα. Activation of ERRα promotes mitochondrial biogenesis through coactivation of PGC-1α, upregulates the expression of OXPHOS genes, increases fatty acid oxidation capacity, and enhances the development of slow-twitch muscle fibers, mimicking resistance exercise adaptations at the molecular level.
KEY BENEFITS
- Exercise mimicry: metabolic adaptations without physical exertion.
- Improved mitochondrial density and respiratory capacity.
- Increased endurance and fat oxidation.
- Potential effects on muscle aging and atrophy.
- Prevention of metabolic disease without the need for exercise.
- Synergy with AICAR for a comprehensive simulation of exercise.
SIDE EFFECTS AND SAFETY
Limited human data. ERR agonism in the context of breast/ovarian cancer raises a theoretical concern due to the family of estrogen-related receptors. Caution is advised in patients with a history of hormone-sensitive malignancies.
RESEARCH AND CLINICAL NOTES
Piccolo et al. (2024): SLU-PP-332 produced a 70% increase in endurance in sedentary mice. Mitochondrial biogenesis and upregulation of OXPHOS genes were confirmed. Novel compound with significant commercial potential.
TARGET PROFILE:
Metabolic medicine, protocols for older patients or those with limited mobility, exercise intolerance programs, and longevity practices.
Additional information
| Weight | ,26 kg |
|---|
You may also like…
Hot
Algal Oil Omega 3 EPA/DHA, 100 capsules
- Vegan source of Omega-3: Schizochytrium microalgae oil, a sustainable alternative to fish oil.
- Cardiovascular health: DHA and EPA help reduce triglycerides, improve circulation, and control blood pressure.
- Brain and cognitive wellness: Supports memory, concentration, and prevents cognitive decline.
- Eye health: DHA is an essential component of the retina, helping maintain optimal vision.
- Anti-inflammatory properties: Alleviates symptoms of arthritis and other chronic inflammatory diseases.
- Suitable for vegans: Free from gluten, lactose, and preservatives.
Related products
New
AOD-9604
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Targeted fat loss without IGF-1-mediated growth effects.
- No effect on blood glucose or insulin sensitivity.
- Fat reduction is well tolerated in patients with metabolic disorders and diabetes.
- It supports body recomposition when combined with exercise.
- Being investigated for cartilage repair (TGA approval in Australia for OA).
New
BPC 5 mg + TB 5 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Faster soft tissue repair than with any of the peptides alone.
- Coverage for localized repair (BPC-157) and systemic repair (TB-500).
- Reduction of inflammation and pain following an injury.
- Recovery of joints, tendons, ligaments, and muscles.
- A convenient, single-vial protocol for injury recovery.
New
GHK-Cu
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- A significant increase in collagen synthesis and improved skin firmness.
- Accelerated healing and reduced scarring.
- Stimulation of the hair follicle and improvement in hair density.
- Systemic anti-aging effect through modulation of gene expression.
- Systemic antioxidant and anti-inflammatory action.
- Bone Regeneration and Nerve Repair in Research Models.
New
KPV
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Powerful anti-inflammatory action in the intestines for IBD, Crohn's disease, and colitis.
- Restoration of intestinal barrier function in intestinal permeability protocols.
- Systemic anti-inflammatory effect without immunosuppression.
- Supports healing and reduces skin inflammation.
- Oral bioavailability for administration targeted at the gastrointestinal tract.
- Safe: extremely low molecular weight and no systemic toxicity.
MOTS-c
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- AMPK-mediated metabolic improvements, including glucose and fat utilization.
- Mimetic properties of exercise.
- Anti-inflammatory and anti-aging effects.
- Supports bone metabolism through osteoblastic activity.
- Protection against age-related physical decline.
- Potential for research on T2DM and obesity management.
New
Retatrutide 20 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
SS-31
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Restoration of mitochondrial function in aged and diseased tissues.
- Improved cardiac function in heart failure.
- Renal protection in ischemia-reperfusion injury.
- Reduction of neuroinflammation.
- Preservation of Muscle Fiber in Aging and Sarcopenia.
- FDA Breakthrough Therapy Designation for Barth Syndrome.
New
Tirzepatide
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 22.5% in SURMOUNT-1.
- A 2.0–2.3% reduction in HbA1c in the SURPASS program.
- Superior glycemic control compared with semaglutide in a direct comparative trial.
- Reduction in triglycerides and LDL.
- Improvement in sleep apnea in the SURMOUNT-OSA trial.
- Approved by the FDA for T2DM as Mounjaro and for obesity as Zepbound.
